AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02037633
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02687386
Drug: Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
Trial: NCT00732069
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
Trial: NCT04217733
Drug: pentoxyifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxyifylline two times daily for 3 months
Trial: NCT04217733
Drug: Mebeverine
RxNorm normalized name: Mebeverine
DrugBank: Mebeverine (DB12554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine 3 times for 3 months
Trial: NCT04217733
Drug: ethosuximide
RxNorm normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ethosuximide 3 times for 3 months
Trial: NCT00007345
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01825928
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
Trial: NCT00484107
Drug: Conjugated Estrogen Cream (Premarin®)
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02055781
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00194987
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
Trial: NCT00542243
Drug: Finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride (5mg) will be given once per day for 6 months.
Trial: NCT01023737
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Trial: NCT01023737
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Trial: NCT00936741
Drug: mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone 300 mg to 1200 mg once daily
Trial: NCT03363971
Drug: Zhi Kang Capsule
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
Trial: NCT04771728
Drug: Metronidazole vaginal suppositories
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
Trial: NCT04771728
Drug: Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
Trial: NCT00315445
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
Trial: NCT02277041
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
Trial: NCT02277041
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
Trial: NCT00400348
Drug: Panzem Nanocrystal Colloidal Dispersion (NCD)
RxNorm normalized name: amphotericin B colloidal dispersion
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Panzem NCD 1,000 mg, four times daily for 28 consecutive days
Trial: NCT00684983
Drug: Lapatinib Ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03712098
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
Trial: NCT02856919
Drug: brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mirvaso® gel (5 mg/g brimonidine tartrate)
Trial: NCT02496494
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus for maintenance immunosupression in kidney transplant recipients
Trial: NCT00959803
Drug: PF-04447943
RxNorm normalized name: PF-04447943
DrugBank: PF-04447943 (DB11953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg solution, oral single dose.
Trial: NCT00959803
Drug: PF-04447943
RxNorm normalized name: PF-04447943
DrugBank: PF-04447943 (DB11953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg solution, oral single dose.
Trial: NCT00959803
Drug: PF-04447943
RxNorm normalized name: PF-04447943
DrugBank: PF-04447943 (DB11953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg solution, oral single dose.
Trial: NCT00959803
Drug: PF-04447943
RxNorm normalized name: PF-04447943
DrugBank: PF-04447943 (DB11953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg solution, oral twice daily for 7 days.
Trial: NCT00949442
Drug: Insulin Glargine (HOE901) [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
Trial: NCT00949442
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets of 1 and 2 mg
Trial: NCT01018823
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
Trial: NCT01018823
Drug: Placebo to Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
Trial: NCT00618618
Drug: Deoxycholic Acid Injection
RxNorm normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Trial: NCT01187303
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
Trial: NCT02522338
Drug: iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml de l'iohexol (300 mgI/ml)
Trial: NCT03787927
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (325mg) will be administered the day before every transfusion.
Trial: NCT03787927
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel (600mg) will be administered the day before every transfusion.
Trial: NCT00359216
Drug: Mometasone furoate nasal spray
RxNorm normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
Trial: NCT01423032
Drug: bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m² iv, day 1+2, q4w
Trial: NCT01423032
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m² iv, days 1-5, q4w
Trial: NCT00003653
Drug: flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
Trial: NCT03511768
Drug: 18F-AlF-NOTA-octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One injection of 18F-AlF-NOTA-octreotide
Trial: NCT01505283
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epidural administration of lidocaine 50 mg
Trial: NCT01651364
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
Trial: NCT00545142
Drug: Abilify(Aripiprazole)
RxNorm normalized name: aripiprazole Injection [Abilify]
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
Trial: NCT00545142
Drug: Depakote(Divalproate)
RxNorm normalized name: Depakote
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
Trial: NCT02273505
Drug: Asasantin (ER)
RxNorm normalized name: Afsantin
DrugBank: Wormwood (DB14291)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02273505
Drug: Persantin
RxNorm normalized name: Persantine
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02273505
Drug: Acetyl salicylic acid (ASA)
RxNorm normalized name: acetyl salicylate
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04643249
Drug: KL1333
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03368807
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed.
Trial: NCT00408239
Drug: YM150
RxNorm normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00408239
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub cutaneous
Trial: NCT04219579
Drug: Antithrombin III, continuous infusion
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin-III is administered continuously
Trial: NCT04219579
Drug: Antithrombin III, Intermittent infusion
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin-III is administered intermittently
Trial: NCT03290625
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
Trial: NCT03290625
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
Trial: NCT02217956
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217956
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03840915
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Trial: NCT04643249
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syrap
Trial: NCT04643249
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03840915
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Trial: NCT03840915
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.
Trial: NCT03840915
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
Trial: NCT03840915
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
Trial: NCT03840915
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Trial: NCT04643249
Drug: Midazolam injection
RxNorm normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution for injection
Trial: NCT04643249
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04643249
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03840915
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Trial: NCT03840915
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Trial: NCT03840915
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
Trial: NCT03840915
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
Trial: NCT02433093
Drug: Basimglurant
RxNorm normalized name: Basimglurant
DrugBank: Basimglurant (DB11833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
Trial: NCT03641976
Drug: A-FOLFOXIRI
RxNorm normalized name: Padimate A
DrugBank: Padimate A (DB11229)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV
Trial: NCT01528176
Drug: 10,000 IU of cholecalciferol for a total of 8 weeks
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
Trial: NCT01376427
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone
Trial: NCT01376427
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine
Trial: NCT01819259
Drug: Nicotine nasal spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
Trial: NCT01171378
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks
Trial: NCT00100906
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with interleukin-2
Trial: NCT00100906
Drug: ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00822211
Drug: Vildagliptin 50 mg bid
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00822211
Drug: Vildagliptin 50 mg qd
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no